TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02687477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Arterial Denervation
Description: Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: patient in the sham group will receive sham procedure
Study: NCT04155788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Exposure
Description: Participants will complete a meal exposure using one of their feared foods.
Study: NCT02309554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm used with ContraGel
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SILCS diaphragm used with 3% Nonoxynol-9
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SILCS diaphragm
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SILCS diaphragm
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
Study: NCT02835625

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Mammography + Digital Breast Tomosynthesis
Description: Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
Study: NCT02309554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
Study: NCT02912013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Me Mini
Description: Home use hair removal device
Study: NCT03406689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.1% Oph Susp
Description: One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.3% Oph Susp
Description: One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tear
Description: One drop Artificial Tears will be instilled 45' prior to the IVI.
Study: NCT02835625

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Digital mammography
Description: Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
Study: NCT01925729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ragweed
Description: ragweed arm only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histamine
Description: histamine arm only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: pseudoephedrine arm only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: oxymetazoline arm only
Study: NCT02641093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
Study: NCT02288247

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT02641093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: gross total surgical resection
Study: NCT02782546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Graft cell infusion
Description: -Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: -GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: -GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: -Continue until neutrophil engraftment as per institutional guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CIML NK cell infusion
Description: -Day +7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: -Start approximately 4 hours after CIML NK cell infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: -Day +6
Study: NCT04454788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
Study: NCT04384692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound imaging
Study: NCT03924193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Participants randomly assigned to this arm will receive 12 weeks of LDX medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination LDX and Cognitive-Behavioral Therapy
Description: Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
Study: NCT03355378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gum chewing
Description: chewing gum orally for 30 minutes
Study: NCT01936168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanochemical Endovenous Ablation (MOCA)
Description: Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Description: Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
Study: NCT01777685

Intervention type: DRUG
Group type: OTHER
Intervention: Sulpiride
Study: NCT04454788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (which may include intravenous Alteplase)
Description: Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
Study: NCT03573700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
Description: Given IV
Study: NCT00933231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Standard dose, Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Standard dose, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Low dose, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Low dose, Oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simulect
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simulect
Description: IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellcept
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellcept
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cellcept
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cellcept
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV and Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV and Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: IV and Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: IV and Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Oral
Study: NCT03133546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
Study: NCT04440982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015
Description: LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.

Intervention type: DRUG
Group type: OTHER
Intervention: LUM015
Description: LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lum Imaging System
Description: UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Study: NCT02921997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Description: Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
Study: NCT03902756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotracheal cuff inflation
Description: Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal cuff inflation
Description: Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
Study: NCT01072032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anklebot (Ankle Robot)
Description: Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anklebot (Ankle Robot)
Description: Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
Study: NCT00638157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daptomycin
Description: Intravenous (i.v.) 6 mg/kg q24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin and gentamicin
Description: i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
Study: NCT00564369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDC HIV testing recommendations
Description: Current vs. prior CDC recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CDC HIV testing recommendations
Description: Current vs. prior CDC recommendations
Study: NCT04101136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin - placebo controlled clinical trial
Description: The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin - placebo controlled clinical trial
Description: The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
Study: NCT04225273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aesthetic 8 ml and Lidocaine
Description: Treatment of nasolabial folds
Study: NCT00411697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Intramuscular injection, 1 dose
Study: NCT01344408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-training
Description: The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-training
Description: The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation
Study: NCT01741480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early warning system monitoring.
Description: General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine care
Study: NCT00218686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: psychoeducational

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: VTC
Study: NCT00927888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Block
Description: Bupivacaine local anesthesia block prior to start of FESS procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is identical in appearance in comparison to active drug.
Study: NCT01182714

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate removal of in-dwelling catheter

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 24 hours delayed removal of catheter
Study: NCT03094208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task balance training
Description: balance exercises with cognitive and motor dual tasks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional balance training
Description: balance exercises
Study: NCT00693784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostat® Disc Augmentation System
Description: Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
Study: NCT01026610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380 90 mg
Description: LB80380 90 mg + placebo tablets, once daily, for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380 150 mg
Description: LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir 0.5 mg
Description: entecavir 0.5 mg tablet, once daily, for 48 weeks
Study: NCT03857685

Intervention type: PROCEDURE
Intervention: In-vitro model
Description: In-vitro model of posterior capsule opacification by culturing the lens capsule
Study: NCT02641093

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 60-66 Gy over 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
Study: NCT02370784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral drug of similar appearance to atorvastatin
Study: NCT03639597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VytronUS Ablation System
Study: NCT01657487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol high dose
Study: NCT03165890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT03780933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c
Description: vitamin c IV 10 G
Study: NCT02685761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midline Vertical
Description: Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Transverse
Description: Cesarean section performed using a transverse skin incision located above the pannus
Study: NCT03504332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracanal disinfection in revascularization
Description: a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracanal disinfection in revascularization
Description: a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
Study: NCT02514187

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclotron-produced 99mTc
Description: Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclotron-produced 99mTc
Description: Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.

Intervention type: DRUG
Group type: OTHER
Intervention: Generator-produced 99mTc
Description: Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.

Intervention type: DRUG
Group type: OTHER
Intervention: Generator-produced 99mTc
Description: Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events.